Flowable Hemostats Market Size & Growth Forecast 2027–2036, By Segments (Application, Origin, End-use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Flowable Hemostats Market size was valued at USD 1.11 Billion in 2026 and is anticipated to grow at 6.15% CAGR from 2027 to 2036, crossing USD 2.02 Billion by 2036. The industry revenue for 2027 is calculated at USD 1.17 Billion.
Get more details on this report
Request Free Sample ReportFlowable Hemostats Market Intelligence Snapshot
Regional Market Dynamics
- North America benefits from advanced healthcare infrastructure, high adoption of innovative surgical products, increasing surgical volumes, and investment in healthcare technology.
- Asia Pacific is expanding through healthcare infrastructure development, rising surgical access, higher healthcare expenditure, and modernization of hospitals and specialized care.
Segment Momentum
- Orthopedic surgery accounted for 20.46% of the market in 2026 because these procedures require effective bleeding control, and flowable hemostats help achieve rapid hemostasis in complex and hard-to-reach surgical sites.
- ASCs are growing rapidly as more procedures shift to outpatient settings, increasing demand for efficient, easy-to-use flowable hemostats that support streamlined workflows, shorter patient stays, and cost-effective surgical care.
Market Expansion Drivers
- Rising global surgical volumes increasing demand for advanced hemostatic treatment solutions
- Increasing trauma and accident cases driving adoption of rapid bleeding control products
- Technological advancements in bioactive hemostatic materials improving clinical effectiveness and adoption
Leading Market Participants
- Top players in the flowable hemostats market include Baxter International Inc. (United States), Becton Dickinson and Company (United States), Johnson & Johnson (United States), Integra LifeSciences Holdings Corporation (United States), Teleflex Incorporated (United States), Pfizer Inc. (United States), Medtronic plc (Ireland), B. Braun Melsungen AG (Germany), CSL Behring (Australia), 3-D Matrix Ltd. (Japan)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 1.11 Billion
- 2027 Estimated Market Size: USD 1.17 Billion
- Projected Market Size: USD 2.02 Billion by 2036
- Growth Forecast: 6.15% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Orthopedic Surgery (Application) | Bovine (Origin) | Hospitals & Clinics (End-use)
- Emerging Opportunity Segment: Cardiovascular Surgery (Application) | Porcine (Origin) | Ambulatory Surgical Centers (ASCs) (End-use)
Market Growth Drivers and Industry Trends
Rising global surgical volumes increasing demand for advanced hemostatic treatment solutions
The growing number of surgical procedures performed across multiple medical specialties is increasing the need for effective intraoperative bleeding management products. This trend will drive the flowable hemostats market growth as surgeons increasingly rely on flowable formulations to control bleeding in complex anatomical sites where conventional methods may be less effective. Their ability to conform to irregular wound surfaces, support rapid hemostasis, and improve surgical efficiency makes these products valuable across both routine and high-risk procedures requiring precise blood loss management.
Increasing trauma and accident cases driving adoption of rapid bleeding control products
A rising incidence of traumatic injuries and emergency medical cases is creating greater demand for products capable of achieving rapid and reliable hemorrhage control. The flowable hemostats market benefits from this growing clinical need because flowable hemostatic agents can be applied quickly in challenging wound environments to help stabilize patients during emergency interventions. Healthcare providers are increasingly incorporating these solutions into trauma care protocols where prompt bleeding control is critical for improving surgical management and supporting effective patient treatment.
Technological advancements in bioactive hemostatic materials improving clinical effectiveness and adoption
Continuous innovation in bioactive materials is enhancing the performance of modern hemostatic products through improved tissue compatibility, faster clot formation, and easier clinical application. These advancements will propel the flowable hemostats market growth by expanding the availability of formulations that deliver reliable hemostasis while integrating efficiently into a wide range of surgical workflows. Improved handling characteristics and enhanced biological performance also encourage broader adoption among healthcare professionals seeking advanced solutions for complex bleeding management.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global surgical volumes increasing demand for advanced hemostatic treatment solutions | 2.4% | High | North America, Europe | High | Near Term |
| Increasing trauma and accident cases driving adoption of rapid bleeding control products | 2.2% | High | Asia Pacific, Latin America | High | Mid Term |
| Technological advancements in bioactive hemostatic materials improving clinical effectiveness and adoption | 2.3% | High | North America, Europe | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America held the largest share of the flowable hemostats market in 2026, supported by advanced healthcare infrastructure, high adoption of innovative surgical products, and strong demand for effective bleeding management solutions. The region's sophisticated hospital and surgical systems facilitate the adoption of advanced hemostatic technologies across a broad range of procedures. Increasing surgical volumes, emphasis on reducing procedure-related complications, and continued advancements in minimally invasive and complex surgical techniques are supporting demand for flowable hemostats. Growing investment in healthcare technology and improvements in clinical practice are also reinforcing the region's established market position.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is projected to experience the fastest growth, driven by expanding healthcare infrastructure, increasing access to advanced surgical procedures, and rising healthcare expenditure. Improvements in hospital capabilities across emerging economies are creating greater opportunities for modern hemostatic products, while growing awareness of advanced surgical technologies is supporting their adoption. The increasing prevalence of chronic conditions requiring surgical intervention, combined with investments in healthcare modernization and improved access to specialized medical care, is expected to strengthen regional demand for flowable hemostats.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Advanced Surgical SupportThe U.S. flowable hemostats market benefits from increasing adoption in complex surgical procedures requiring rapid bleeding control. Hospitals continue evaluating products that improve procedural efficiency, reduce complications, and integrate easily into diverse surgical specialties.
Germany 🇩🇪
Precision Surgery AdoptionGermany emphasizes flowable hemostats that support precise bleeding management during advanced surgical procedures. Healthcare providers prioritize clinically validated products offering reliable handling characteristics and compatibility with minimally invasive surgical techniques.
Japan 🇯🇵
Minimally Invasive IntegrationJapan continues incorporating flowable hemostats into minimally invasive and specialized surgical procedures to improve intraoperative bleeding control. Hospitals value products that provide consistent performance while supporting efficient surgical workflows and patient care quality.
South Korea 🇰🇷
Surgical Innovation DemandSouth Korea is expanding use of flowable hemostats as hospitals adopt advanced surgical technologies across multiple specialties. Clinical teams increasingly seek products that enhance procedural precision and support effective management of difficult bleeding sites.
France 🇫🇷
Clinical Performance FocusFrance continues strengthening adoption of flowable hemostats in operating rooms where effective bleeding control is essential for surgical outcomes. Healthcare providers prioritize products with established clinical performance and ease of application across varied procedures.
Italy 🇮🇹
Procedure Efficiency SupportItaly is increasing utilization of flowable hemostats to support efficient bleeding management in general and specialized surgery. Hospitals are evaluating products that simplify surgical workflows while maintaining dependable hemostatic performance across diverse clinical settings.
Segment Leadership and Growth Trends
Flowable Hemostats Market Share (%), by Application, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportApplication Segment Analysis: Orthopedic Surgery (Largest Segment) vs Cardiovascular Surgery (Fastest-Growing Segment)
The orthopedic surgery segment dominated the flowable hemostats market and accounted for a 20.46% share in 2026. Orthopedic procedures frequently involve extensive bone and tissue manipulation, creating a significant need for effective bleeding control during surgery. Flowable hemostats are widely utilized in these procedures because they can conform to irregular surgical sites and help surgeons achieve rapid hemostasis in areas that may be difficult to access through conventional methods. The increasing volume of orthopedic interventions and growing focus on improving surgical outcomes continue to support the segment’s leading position.
The cardiovascular surgery segment is witnessing the fastest growth due to the critical importance of precise bleeding management in complex cardiac and vascular procedures. Surgeons increasingly rely on advanced hemostatic products to enhance procedural efficiency and reduce complications associated with excessive bleeding. The growing adoption of sophisticated surgical techniques and the rising demand for specialized cardiovascular interventions are contributing to the rapid expansion of this segment.
Origin Segment Analysis: Bovine (Largest Segment) vs Porcine (Fastest-Growing Segment)
The bovine origin segment held the largest share of the market in 2026. Its leadership is supported by the long-standing use of bovine-derived materials in surgical hemostatic products and their established clinical acceptance across a broad range of procedures. Healthcare providers often favor these products because of their proven effectiveness in achieving localized bleeding control and their extensive utilization within hospital settings.
The porcine origin segment is emerging as the fastest-growing category as manufacturers continue to expand product offerings based on alternative biological sources. Increasing demand for diversified hemostatic solutions and ongoing innovation in biomaterial technologies are supporting greater adoption of porcine-derived products. Their expanding presence across surgical applications is contributing to the segment’s accelerated growth trajectory.
End-use Segment Analysis: Hospitals & Clinics (Largest Segment) vs Ambulatory Surgical Centers (ASCs) (Fastest-Growing Segment)
The hospitals and clinics segment represented the largest share of the flowable hemostats market in 2026. These healthcare facilities perform a high volume of surgical procedures across multiple specialties, creating consistent demand for advanced hemostatic products. Hospitals and clinics also possess the specialized infrastructure, surgical expertise, and patient care capabilities required for complex operations where effective bleeding management is essential.
The ambulatory surgical centers (ASCs) segment is the fastest-growing end-use category, driven by the increasing shift toward outpatient surgical care. ASCs are gaining popularity because they offer efficient procedural workflows, shorter patient stays, and cost-effective treatment environments. As more surgical procedures are performed in ambulatory settings, demand for reliable and easy-to-use flowable hemostats is expected to increase, supporting the growth of this segment.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Application | General Surgery, Cardiovascular Surgery, Orthopedic Surgery, Gynecological Surgery, Neurosurgery, Reconstructive Surgery, Others | Orthopedic Surgery | Cardiovascular Surgery |
| Origin | Bovine, Porcine | Bovine | Porcine |
| End-use | Hospitals & Clinics, Ambulatory Surgical Centers (ASCs), Others | Hospitals & Clinics | Ambulatory Surgical Centers (ASCs) |
Competitive Landscape and Market Positioning
Prominent players in the flowable hemostats market:
- Baxter International, Inc. (United States)
- Becton Dickinson and Company (United States)
- Johnson & Johnson (United States)
- Integra LifeSciences Holdings Corporation (United States)
- Teleflex Incorporated (United States)
- Pfizer, Inc. (United States)
- Medtronic plc (Ireland)
- B. Braun Melsungen AG (Germany)
- CSL Behring (Australia)
- 3-D Matrix Ltd. (Japan)
Competition in the flowable hemostats market is increasingly shaped by the pursuit of improved surgical outcomes, ease of application, and compatibility across complex procedures. Manufacturers are differentiating through formulation advancements, delivery mechanisms, and products designed to address specific clinical challenges rather than competing solely on traditional bleeding control capabilities. Established medical technology providers continue to leverage clinical experience and healthcare relationships, while specialized innovators are focusing on targeted surgical applications and material improvements. The market is moving toward greater emphasis on procedural efficiency and physician confidence as healthcare systems prioritize solutions that support predictable surgical performance.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Baxter International Inc. (United States) | |||||||
| Becton Dickinson and Company (United States) | |||||||
| Johnson & Johnson (United States) | |||||||
| Integra LifeSciences Holdings Corporation (United States) | |||||||
| Teleflex Incorporated (United States) | |||||||
| Pfizer Inc. (United States) | |||||||
| Medtronic plc (Ireland) | |||||||
| B. Braun Melsungen AG (Germany) | |||||||
| CSL Behring (Australia) | |||||||
| 3-D Matrix Ltd. (Japan) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Baxter International | Feb-25 | Baxter International launched a room-temperature version of its HEMOPATCH Sealing Hemostat in Europe, designed to improve product accessibility and simplify storage requirements during surgical procedures. This helped the company strengthen its advanced hemostasis portfolio and expand adoption across hospital operating rooms. |
| Baxter International Inc. | Mar-23 | Baxter International Inc. launched FLOSEAL + RECOTHROM, the first active flowable hemostat utilizing recombinant thrombin technology, at the AORN Global Surgical Conference & Expo 2023. This helped the company strengthen its surgical hemostasis portfolio and improve product preparation efficiency. |
| Medcura | Dec-22 | Medcura received FDA breakthrough device designation for its LifeGel flowable technology that controls bleeding during surgery for procedures where swelling cannot be tolerated. This helped the company expand its sales in the U.S. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Flowable Hemostats Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Mechanism of Action | Mechanical Matrix-Based, Thrombin-Based, Combination Hemostatic |
| Delivery Format | Syringe-Based, Applicator-Based, Dual-Syringe/Mixing Systems |
| Procurement Channel | Direct Hospital Procurement, Group Purchasing Organizations, Distributors & Specialty Suppliers |
Flowable Hemostats Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Surgical Procedure Opportunity Mapping |
|
| Reimbursement & Market Access Assessment |
|
| Unmet Clinical Needs & Product Differentiation |
|
Need a different cut of the data?
Request Custom ResearchHow large is the flowable hemostats market?
How is the flowable hemostats industry expected to grow over the next 10 years?
Why are flowable hemostats seeing increased adoption in surgical care?
How are bioactive material innovations strengthening the flowable hemostats market?
Why is orthopedic surgery the largest application segment in the flowable hemostats market?
Why are ambulatory surgical centers (ASCs) the fastest-growing end-use segment?
Why does North America lead the flowable hemostats market?
What is driving flowable hemostats growth in Asia Pacific?
Who holds a significant market share in the flowable hemostats landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization